A Phase I/Ib Study to Evaluate Safety and Pharmacokinetics of SAR408701 Administered Intravenously as Monotherapy and in Combination With Other Anti-tumor Drug in Japanese Patients With Advanced Malignant Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs SAR 408701 (Primary) ; Dexamethasone; Diphenhydramine; Naphazoline; Tipiracil/trifluridine
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Sanofi
- 11 Dec 2018 Planned End Date changed from 1 Nov 2018 to 1 Jan 2019.
- 11 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Jan 2019.
- 24 Oct 2018 Planned End Date changed from 27 Sep 2018 to 1 Nov 2018.